Abstract
O ne of the most difficult challenges that policy-makers will face in the next 10 years is tackling the ethical considerations involved in the coverage of so-called ‘lifestyle’ drugs. Should health plans provide coverage for such drugs? If so, should limits be set? And will limits jeopardise physician-patient relationships? At the sixth annual Drug Information Association symposium on Quality of Life Evaluation [ Hilton Head, South Carolina, US; March 1999 ], Dr James Sabin shared his experience in establishing coverage policies and provided some answers to these questions. *
This is a preview of subscription content, log in via an institution to check access.
Additional information
* Dr Sabin is associate clinical professor and codirector of the Center for Ethics in Managed Care at the Harvard Pilgrim Health Care and Harvard Medical School, US.
Rights and permissions
About this article
Cite this article
Doshi, D. Ethical considerations in the coverage of ‘lifestyle’ drugs. Pharmacoecon. Outcomes News 213, 3–4 (1999). https://doi.org/10.1007/BF03290018
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03290018